"Omega-3 fatty acids have been known for their cardioprotective effects and they have broad anti-inflammatory properties, ...

A novel immunoglobulin A nephropathy (IgAN) drug cut proteinuria in half, according to interim findings from the ongoing ...

Significant reductions in proteinuria, estimated glomerular filtration rate stability of the C3/C3b inhibitor were also ...

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

Patients who develop LN within 1 to 5 years after SLE onset may face poorer renal outcomes compared with those who develop the disease earlier.

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

PFS in Phase 3 HARMONi study was met with statistical significance, but OS was not. Click here to find out why SMMT stock is ...

Coinbase joins the S&P 500, marking a milestone for Bitcoin, further highlighting Bitcoin’s strong performance, outperforming gold and the S&P 500 over the years. Coinbase Global Inc. (NASDAQ: COIN) ...

“This reverses the effects of the EGFR inhibition in the skin only ... demonstrated a 74% success rate compared with 28% in the placebo group (P = .0001). The lower-dose formulation (0.03% ...

The Rybrevant-Lazcluze combo significantly reduced the risk of death by 25% versus Tagrisso in patients with newly diagnosed advanced EGFR-mutated NSCLC, according to data from the phase 3 ...

SC amivantamab, in combination with LAZCLUZE, is recommended for adult patients with advanced NSCLC with epidermal growth factor receptor (EGFR) mutations. The recommended dosing is weekly from Weeks ...